Carlos Jose Pirola

Resmetirom is an oral selective THR-β agonist conditionally approved for the treatment of patients with noncirrhotic MASH with moderate to advanced fibrosis. Resmetirom restores mitochondrial and hepatic metabolic function; reduces atherogenic lipids; improves hepatic steatosis, inflammation, and fibrosis; and has no significant effect on THR-α. To view this Bench to Bedside, open or download the PDF.

Statistical analysis We compared taxon abundances at the genus level across genotypes assuming a dominant model of inheritance and comparing YY with XY + XX, in which X is the risk allele. The use of a dominant model for all tested variants is justified as we performed pairwise comparisons of the relative abundance of each taxon.

ABSTRACT Introduction: Fatty liver disease, defined by the presence of liver fat infiltration, is part of a cluster of disorders that occur in the context of metabolic syndrome. Epigenetic factors – defined as stable and heritable changes in gene expression without changes in the DNA sequence – may not only play an important role in the disease development in adulthood, but they may start exerting their influence in the prenatal stage.